Gira Sarabhai (1923-2021): A Deliberate Life thewire.in - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thewire.in Daily Mail and Mail on Sunday newspapers.
Read more about Ambalal Sarabhai Enterprises reports standalone net loss of Rs 8.93 crore in the March 2021 quarter on Business Standard. Reported sales nil
મહામારી જેવા મોટા સંકટના સમયે શ્રેષ્ઠીઓ સાંભરે ! sandesh.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sandesh.com Daily Mail and Mail on Sunday newspapers.
Ambalal Sarabhai Enterprises (ASE) hit an upper circuit of 20% at Rs 33.40 after the company said that its subsidiary has ramped up the production of API Amphotericin B.
The company said that India is witnessing an outbreak of Mucormycosis - a very fast spreading fungal infection especially for post-COVID infection and recovery because of low immune system in the patients. The most recommended treatment for this infection is Amphotericin B injection.
Synbiotics, a subsidiary of ASE is the only manufacturer of the active pharmaceutical ingredient (API) Amphotericin B in India. Looking at the current outbreak of Mucormycosis and expected requirement, Synbiotics has ramped up the manufacturing capacity to meet the requirement of this most effective anti-fungal antibiotic in the post-COVID crisis.